Campath Linked to Autoimmune Diseases, Bleeding

Last Updated on June 26, 2017

Important Information

Attorneys working with ClassAction.org are no longer investigating this matter. The information here is for reference only. A list of open investigations and lawsuits can be viewed here.

Comments |

At A Glance

This Alert Affects
Patients given Campath as part of their treatment for B-CLL, or off-label for Multiple Sclerosis
Damages
Idiopathic Thrombocytopenic Pupura (ITP), autoimmune disease leading to bleeding and bruising.
Company(ies)
Genzyme, Sanofi-Aventis.
Additional Details
Patients and authorities have been contacted by the manufacturer to advise about side effects and risks.
Date
FDA warning issued 2007